This article includes a list of references, but its sources remain unclear because it has insufficient inline citations. (May 2013) (Learn how and when to remove this template message)
Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human and other animal. In other words, immunogenicity is the ability to induce a humoral and/or cell-mediated immune responses.
Distinction has to be made between wanted and unwanted immunogenicity.
- Wanted immunogenicity is typically related with vaccines, where the injection of an antigen (the vaccine) provokes an immune response against the pathogen (virus, bacteria...) aiming at protecting the organism. Vaccine development is a complex multistep process, immunogenicity being at the center of the vaccine efficiency.
- Unwanted immunogenicity is an immune response by an organism against a therapeutic antigen (ex. recombinant protein, or monoclonal antibody). This reaction leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. The prediction of the immunogenic potential of novel protein therapeutics is thus a challenge in biotherapy.
Antigenic immunogenic potency
- Proteins or polysaccharides are used for studies of humoral immune response.
- Only proteins can serve as immunogens for cell-mediated immunity.
In the rush to deliver novel biologics to market, developers have, on occasion, overlooked factors that contribute to protein immunogenicity. In addition, autologous or human-like proteins have proven to be surprisingly immunogenic in some applications, suggesting that assumptions about immune tolerance, too, require careful consideration in biologics design.
Years of thorough study of the parameters influencing vaccine efficacy allow parallels to be drawn for protein therapeutics. Factors including delivery route, delivery vehicle, dose regimen, aggregation, innate immune system activation, and the ability of the protein to interface with the humoral (B cell) and cellular (T cell) immune systems, all impact the potential immunogenicity of vaccine immunogens when delivered to humans (for reviews related to unwanted immunogenicity determinants, see references below).
Like vaccines, protein therapeutics can engender both cellular and humoral immune responses. Anti-drug antibodies (ADA) may neutralize the therapeutic effects of the drug and/or alter its pharmacokinetics. B cells are certainly involved in this immune response when IgG class ADA are observed, because antibody isotype switching is a hallmark of B-dependent antigens.
More serious adverse events can be provoked if ADA cross-react with a critical autologous protein. Examples of adverse ADA responses include autoimmune thrombocytopenia (ITP) following exposure to recombinant thrombopoietin, and pure red cell aplasia, which was associated with a particular formulation of erythropoietin (Eprex). Since the impact of immunogenicity can be quite severe, regulatory agencies are developing risk-based guidelines for immunogenicity screening.
Immunogenicity is influenced by multiple characteristics of an antigen:
- Degradability (ability to be processed & presented to T cells)
In silico screening. T cell epitope content, which is one of the factors that contributes to the risk of immunogenicity can now be measured relatively accurately using in silico tools. Immunoinformatics algorithms for identifying T-cell epitopes are now being applied to triage protein therapeutics into higher risk and low risk categories.
One approach is to parse protein sequences into overlapping 9-mer peptide frames, each of which is then evaluated for binding potential to each of eight common class II HLA alleles that “cover” the genetic backgrounds of most humans worldwide. By calculating the density of high-scoring frames within a protein, it is possible to estimate a protein’s overall “immunogenicity score”. In addition, sub-regions of densely packed high scoring frames or “clusters” of potential immunogenicity can be identified, and cluster scores can be calculated and compiled. Given the resulting “immunogenicity score” of a protein, and taking into consideration other determinants of immunogenicity as described above, it is possible to make an informed decision about the likelihood that a protein will provoke an immune response.
Using this approach, the clinical immunogenicity of a novel protein therapeutics can be calculated and consequently a number of biotech companies have integrated in silico immunogenicity into their pre-clinical process as they develop new protein drugs.
T cell epitopes
De-immunization by epitope modification is a strategy for reducing immunogenicity based on disruption of HLA binding, an underlying requirement for T cell stimulation. The idea of rational epitope modification is rooted in the natural process that occurs when tumor cells and pathogens evolve to escape immune pressure by accumulating mutations that reduce the binding of their constituent epitopes to host HLA, rendering the host cell unable to “signal” to T cells the presence of the tumor or pathogen. Deimmunized protein therapeutics are now entering the clinic; initial results appear to support this approach to reducing immunogenicity risk. Several methods exist for deimmunization by epitope modification for reduced immunologic potential in-vitro, in-vivo and ex-vivo.
|Look up immunogenicity in Wiktionary, the free dictionary.|
- Leroux-Roels G. (2011). "Vaccine development". Perspectives in Vaccinology. 1 (4): 115–150. doi:10.1016/j.pervac.2011.05.005. PMID 19348557.
- De Groot A.S.; Scott D.W. (2007). "Immunogenicity of protein therapeutics". Trends in Immunology. 28 (11): 482–490. doi:10.1016/j.it.2007.07.011. PMID 17964218.
- Baker M.P.; et al. (October 2010). "Immunogenicity of protein therapeutics". Self Nonself. 1 (4): 314–322. doi:10.4161/self.1.4.13904. PMC . PMID 21487506.
- Baker, M. P; Reynolds, H. M; Lumicisi, B; Bryson, C. J (2010). "Immunogenicity of protein therapeutics: The key causes, consequences and challenges". Self/nonself. 1 (4): 314–322. doi:10.4161/self.1.4.13904. PMC . PMID 21487506.
- Jawa, Vibha; AS Degroot; L Cousens; M Awwad; H. Kropshofer; E. Wakshull (December 2013). "T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation". Clinical Immunology. 149 (3): 534–555. doi:10.1016/j.clim.2013.09.006. PMID 24263283.
- Immunologists' Toolbox: Immunization. In: Charles Janeway, Paul Travers, Mark Walport, Mark Shlomchik: Immunobiology. The Immune System in Health and Disease. 6th Edition. Garland Science, New York 2004, ISBN 0-8153-4101-6, p. 683–684
- Descotes Jacques (Mar 2009). "Immunotoxicity of monoclonal antibodies". MAbs. 1 (2): 104–111. doi:10.4161/mabs.1.2.7909. PMC . PMID 20061816.
- The European Immunogenicity Platform http://www.e-i-p.eu
- De Groot AS, Martin W (2009). "Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics". Clin Immunol. 131 (2): 189–201. doi:10.1016/j.clim.2009.01.009. PMID 19269256.